ISSN: 2578-4625
Authors: Bhalchandra Mirlekar
Recent efforts for cancer treatment include chemotherapy, radiation therapy, surgery, molecular targeted therapy and immunotherapy. Most of these therapies can be beneficial in patients with early stage disease, but this therapy is ineffective to treat advanced stage of metastatic cancer. During cancer initiation and metastasis innate or acquired immune suppression are among the reason for reduced responsiveness to therapy. Majority of the studies of decreased responsiveness focus on marked “immune-suppression†within tumor microenvironment. Several studies have emphasized the impact of therapy-induced physiological changes in cancer cell that can inhibit anti-tumor effect by promoting immunosuppression. These undesired host effects can enhance tumor growth and even malignancy. These effects fall out as a result of systemic release of various regulatory cytokines, chemokines and host immune regulatory cells, which can infiltrate into the tumor. In short, the preferred therapy to target tumor can be offset by reactive effector immune response; by preventing or combating the immunosuppression represents a potentially new approach to boost the effectiveness of systemic and local cancer therapies.
Keywords: Antitumor; Cancer Therapy; Immunosuppression
